-
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
•
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules…
-
Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch
•
China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) to terminate their strategic partnership, which was initially formed in December 2020 to support the launch of the hypoglycemic drug chiglitazar (Bilessglu) for type 2 diabetes in 19 provinces, including Henan,…
-
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
•
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic partnership with domestic pharmaceutical firm Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267). The collaboration will combine MindRank’s AI platform technology with Hisun Pharmaceutical’s research and development (R&D) capabilities and manufacturing resources to advance the field…
-
Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li Yan, its former director and president, is currently under investigation for alleged corruption, embezzlement, bribery, and receipt of bribes as a non-state employee during the company’s business operations from 2019 to 2022. Li Yan, an…
-
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HS336, intended for the treatment of advanced solid tumors. HS336: A Novel SHP2 Inhibitor for Anti-Tumor TherapyHS336 is a…
-
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
•
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply issues, prompting the company to seek additional production and supply agreements. The latest deal was struck with Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), following a similar agreement with Zhejiang Huahai Pharmaceutical Co., Ltd (SHA:…
